Flolipid is owned by Tcg Fluent Pharma.
Flolipid contains Simvastatin.
Flolipid has a total of 2 drug patents out of which 0 drug patents have expired.
Flolipid was authorised for market use on 21 April, 2016.
Flolipid is available in suspension;oral dosage forms.
The generics of Flolipid are possible to be released after 23 February, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10300041 | TCG FLUENT PHARMA | Liquid oral simvastatin compositions |
Apr, 2027
(3 years from now) | |
US9597289 | TCG FLUENT PHARMA | Liquid oral simvastatin compositions |
Feb, 2030
(6 years from now) |
Drugs and Companies using SIMVASTATIN ingredient
Market Authorisation Date: 21 April, 2016
Treatment: NA
Dosage: SUSPENSION;ORAL
4
United States
1
Cyprus
1
Slovenia
1
China
1
Australia
1
Denmark
1
Portugal
1
Spain
1
Poland
1
Japan
1
Austria
1
United Kingdom
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic